Cognition Therapeutics (CGTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CGTX Stock Price Chart Interactive Chart >
CGTX Price/Volume Stats
| Current price | $2.68 | 52-week high | $13.80 |
| Prev. close | $2.49 | 52-week low | $2.31 |
| Day low | $2.50 | Volume | 36,700 |
| Day high | $2.79 | Avg. volume | 72,940 |
| 50-day MA | $2.89 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 60.56M |
Cognition Therapeutics (CGTX) Company Bio
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Latest CGTX News From Around the Web
Below are the latest news stories about Cognition Therapeutics Inc that investors may wish to consider to help them evaluate CGTX as an investment opportunity.
Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative TherapeuticsAnthony Caggiano, M.D., Ph.D., Participating on February 15th Panel: “Exploring the Possibilities of Developing Neurodegenerative Therapeutics”PURCHASE, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases, today announced that Anthony Caggiano, M.D., Ph.D., chief medical officer and head of R&D, will participate in a panel discussion during the annual BIO CEO & Inv |
CGTX stock gains as company highlights upcoming milestones with Alzheimers in focusCognition Therapeutics (CGTX) has added ~8.3% on below-average volume after the company announced its clinical milestones for 2022.During the year, Purchase, New York-based |
Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today provided a summary of the Company’s 2021 accomplishments and outlined upcoming milestones anticipated in the year ahead. Key 2021 Financial A |
Companies Like Cognition Therapeutics (NASDAQ:CGTX) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s DiseaseNEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases, today announced that the company has been awarded a Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). This grant will fund preclinical studies of two sigma-2 (σ-2) receptor modulators in animal models of Parkinson’s disease that will be led by Cognition The |
CGTX Price Returns
| 1-mo | -6.94% |
| 3-mo | -7.59% |
| 6-mo | -67.59% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -57.59% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...